CTDH stock forecast
Our latest prediction for Cyclo Therapeutics, Inc.'s stock price was made on the Sept. 18, 2019 when the stock price was at 0.18$.
In the short term (2weeks), CTDH's stock price should outperform the market by 5.08%. During that period the price should oscillate between -10.94% and +23.20%.
In the medium term (3months), CTDH's stock price should outperform the market by 12.79%. During that period the price should oscillate between -24.13% and +68.12%.Get email alerts
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -0.05$ per share.
The book value per share is None$
Three months stock forecastSept. 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|